Comparative Effect of 1.2% Atorvastatin Gel and 1.2% Rosuvastatin as a Local Drug Delivery in Treatment of Intra-Bony Defects in Chronic Periodontitis

Abstract

Background: The present study was aimed to evaluate the efficacy of 1.2% Atorvastatin (ATV) with 1.2% Rosuvastatin (RSV) as local drug delivery for treatment of Chronic Periodontitis (CP). Materials and Methods: Forty patients were equally divided into two groups. Group A underwent scaling and root debridement and 1.2% ATV gel (1.2 mg/0.1 mL) was placed, whereas group B received scaling and root debridement and RSV (1.2 mg/0.1 ml) was placed. Results: The results showed that both the groups had improvement in all the recorded parameters, and the results obtained were statistically significant. When comparison was made between the groups, no significant difference was obtained between atorvastatin and rosuvastatin at baseline in all recorded parameters. However, after 6 months significant improvement was recorded in CAL (Clinical attachment level) and PD (Probing depth). The plaque index (PI) and gingival index (GI) score however showed improvement, but it did not attain the level of significance. Conclusion: The present study showed improvement in clinical parameters with the use of ATV and RSV gel when used in combination with scaling and root planing (SRP) in CP patients. Patients with RSV gel showed up significantly better than the ones in which ATV gel was placed.

Local Delivery and Controlled Release Drugs Systems: A New Approach for the Clinical Treatment of Periodontitis Therapy

“…Their application has been demonstrated to produce effective benefits in periodontal health and sustained drug release; for example, Xu et al [25] produced and tested an injectable and thermosensitive gel loaded with aspirin and erythropoietin, which had excellent biocompatibility, was easily prepared, and could continuously release the active substance for at least 21 days. Moreover, there are interesting studies about gels loaded with encapsulated osteogenesis drugs [26,27]. For instance, the biological hydrogel of recombinant human Fibroblast Growth Factor type 2 (rhFGF-2) in a hyaluronic acid (HA) has been tested, showing more PD reduction (5.5 versus 2.9 mm), PAL gains (4.8 versus 2.2 mm), and shallower residual PD (4.2 versus 6.6 mm) than controls [114].…”

Polymeric Gel Systems Cytotoxicity and Drug Release as Key Features for their Effective Application in Various Fields of Addressed Pharmaceuticals Delivery

“…In the following study [ 85 ], methylcellulose-based gels containing atorvastatin and rosuvastatin were tested in vivo on patients with periodontitis. Statins had osteoblastic properties and prevented alveolar bone resorption, as evidenced by a significant improvement after 6 months of gel treatment.…”

“…However, the works [ 84 , 85 ] did not study the processes of alveolar bone restoration and collagen regeneration. In [ 86 ], baicalin and clove oil were loaded into a nanogel based on poloxamers 407 and 188.…”